证券日报网讯 12月30日，人民同泰在互动平台回答投资者提问时表示，公司属于医药流通企业，凭 借"批零一体化"的经营模式构筑差异化竞争优势。主要销售化学药、中成药、生物制品，同时销售医疗 器械、中药饮片、保健食品、日用品、玻璃仪器、化学试剂等，公司依托区域市场规模及渠道覆盖优 势，保障药品供应，服务公众健康。 （文章来源：证券日报） ...

Group 1 - The core viewpoint of the news is that Dajia Weikang's stock performance and financial metrics indicate a mixed outlook, with a decline in net profit despite a slight increase in revenue [1][2]. - On December 24, Dajia Weikang's stock price fell by 0.85%, with a trading volume of 121 million yuan. The financing buy-in amount was 10.85 million yuan, while the financing repayment was 13.39 million yuan, resulting in a net financing outflow of 2.55 million yuan [1]. - As of December 24, the total margin balance for Dajia Weikang was 75.37 million yuan, with the financing balance accounting for 2.85% of the circulating market value, indicating a high level compared to the past year [1]. Group 2 - As of December 10, the number of shareholders for Dajia Weikang was 16,000, a decrease of 2.42% from the previous period, while the average circulating shares per person increased by 2.48% to 8,620 shares [2]. - For the period from January to September 2025, Dajia Weikang reported operating revenue of 4.13 billion yuan, a year-on-year increase of 3.69%, but the net profit attributable to shareholders decreased by 86.02% to 5.10 million yuan [2]. - Dajia Weikang has distributed a total of 42.59 million yuan in dividends since its A-share listing, with 35.57 million yuan distributed over the past three years [3].

截至12月10日，达嘉维康股东户数1.60万，较上期减少2.42%；人均流通股8620股，较上期增加2.48%。 2025年1月-9月，达嘉维康实现营业收入41.30亿元，同比增长3.69%；归母净利润509.74万元，同比减少 86.02%。 分红方面，达嘉维康A股上市后累计派现4259.09万元。近三年，累计派现3556.97万元。 机构持仓方面，截止2025年9月30日，达嘉维康十大流通股东中，诺安多策略混合A（320016）退出十 大流通股东之列。 责任编辑：小浪快报 12月23日，达嘉维康跌1.30%，成交额1.61亿元。两融数据显示，当日达嘉维康获融资买入额1798.91万 元，融资偿还1087.17万元，融资净买入711.74万元。截至12月23日，达嘉维康融资融券余额合计 7791.76万元。 融资方面，达嘉维康当日融资买入1798.91万元。当前融资余额7772.47万元，占流通市值的2.92%，融 资余额超过近一年70%分位水平，处于较高位。 融券方面，达嘉维康12月23日融券偿还300.00股，融券卖出300.00股，按当日收盘价计算，卖出金额 3882.00元；融券余量1.49万股，融 ...

12月23日，百洋股份盘中下跌2.07%，截至09:43，报7.10元/股，成交1840.82万元，换手率0.77%，总市 值24.59亿元。 资金流向方面，主力资金净流入33.51万元，大单买入127.30万元，占比6.92%，卖出93.79万元，占比 5.10%。 百洋股份今年以来股价涨50.11%，近5个交易日涨6.77%，近20日涨1.28%，近60日涨16.01%。 今年以来百洋股份已经2次登上龙虎榜，最近一次登上龙虎榜为7月4日，当日龙虎榜净买入1247.16万 元；买入总计6131.92万元 ，占总成交额比12.65%；卖出总计4884.76万元 ，占总成交额比10.08%。 百洋股份所属申万行业为：农林牧渔-饲料-水产饲料。所属概念板块包括：水产品、饲料、乡村振兴、 微盘股、预制菜等。 截至9月30日，百洋股份股东户数1.59万，较上期增加7.42%；人均流通股21005股，较上期减少7.18%。 2025年1月-9月，百洋股份实现营业收入29.52亿元，同比增长38.77%；归母净利润3612.80万元，同比增 长218.12%。 分红方面，百洋股份A股上市后累计派现2.07亿元。近三年，累 ...

截至11月28日，智飞生物股东户数12.80万，较上期减少1.63%；人均流通股11053股，较上期增加 1.66%。2025年1月-9月，智飞生物实现营业收入76.27亿元，同比减少66.53%；归母净利润-12.06亿元， 同比减少156.10%。 分红方面，智飞生物A股上市后累计派现73.18亿元。近三年，累计派现31.94亿元。 机构持仓方面，截止2025年9月30日，智飞生物十大流通股东中，香港中央结算有限公司位居第三大流 通股东，持股3356.08万股，相比上期减少278.88万股。易方达创业板ETF（159915）位居第五大流通股 东，持股2415.90万股，相比上期减少405.65万股。华泰柏瑞沪深300ETF（510300）位居第六大流通股 东，持股2042.08万股，相比上期减少96.46万股。招商国证生物医药指数A（161726）位居第九大流通 股东，持股1615.47万股，相比上期减少274.48万股。易方达沪深300医药ETF（512010）位居第十大流 通股东，持股1499.56万股，相比上期减少470.11万股。 责任编辑：小浪快报 12月19日，智飞生物涨0.68%，成交额1. ...

Core Insights - The article highlights that certain cyclical and consumer sectors have underperformed the market for three consecutive years, indicating potential investment opportunities in these areas [1][6]. Industry Analysis - The sectors with the highest expected net profit growth for next year include: - Agriculture (planting, breeding, feed) - Internet e-commerce - Leisure food - Beauty care (personal care products, cosmetics) - Light manufacturing (household goods, entertainment products) - Automotive services - Social services (hotel catering, tourist attractions) - Cement [1][6]. - Historical data since 2010 shows that industries that have underperformed for three consecutive years and then outperformed in the fourth year include: - Food and beverage (leisure food, food processing, seasoning and fermentation products, non-brewed beverages) - Agriculture (breeding, feed, planting) - Beauty care (cosmetics, personal care products) - Infrastructure - Tourist attractions [1][6]. Financial Metrics - Expected net profit growth rates for various sectors by 2026 are as follows: - Planting: 41% - Breeding: 32% - Chemical fiber: 42% - Chemical raw materials: 24% - Automotive services: 24% - Internet e-commerce: 44% - Cement: 22% [2][7]. - The PE (Price to Earnings) ratios over the past three years indicate reasonable valuation levels for several sectors, with notable figures such as: - Planting at 75% - Chemical fiber at 94% - Internet e-commerce at 69% [2][7].

Group 1 - Company Qianjiang Biochemical (SH 600796) announced on December 12 that it signed a maximum guarantee contract with Zhejiang Haining Rural Commercial Bank for a credit facility requested by Guangyao Thermal Power, providing a joint liability guarantee of up to 19.64285 million yuan based on its shareholding ratio [1] - The revenue composition of Qianjiang Biochemical for the year 2024 is as follows: wastewater treatment and recycling 28.2%, engineering installation and material sales 22.76%, waste transportation and disposal 18.53%, biological products 14.5%, thermal power industry 9.85%, and water treatment and supply 5.43% [1] - As of the report date, the market capitalization of Qianjiang Biochemical is 5.2 billion yuan [1]

更公司 查老板 童关系 查风险 都 在 用 的 商 业 查 词 工 具 (× 云南白药集团股份有限公司 天眼一下 国家中小企业发展子基金旗下机构 基本信息 217 上市信息 999+ 法律诉讼 413 经营风险 81 经营信息 999+ 主要股东 2 ● 品股权结构 股权变更历程140 ? 最新公示3 工商登记5 历史主要股东2 序号 股份类型 股东名称 云南省国有股权运营管理有限公司 器 1 流通A股 大股东 | 圆 省管国企 新华都实业集团股份有限公司 品 2 流通A股 大股东 云南合和（集团）股份有限公司 器 3 流通A股 大股东 | 国有独资 每经AI快讯，天眼查工商信息显示，近日，云南白药（000538）发生工商变更，董明卸任法定代表人，王明辉卸任董事长，由张文学接任，注册资本由约 10.4亿元人民币增至约17.8亿元人民币，同时，多位高管发生变更。云南白药集团股份有限公司成立于1993年11月，经营范围含化学原料药、化学药制剂、 中成药、中药材、生物制品、医疗器械等的销售，信息技术、科技及经济技术咨询服务，货物进出口等。股东信息显示，该公司由云南省国有股权运营管理 有限公司、新华都（002264） ...

Group 1: Shanghai International Economic Center Development - The successful launch of China's first domestic segmented production pilot project for biological products [2] - Initiation of a pilot program for expanding value-added telecommunications services to attract foreign investment [2] - Establishment of a digital and standardized transformation in the domestic reinsurance industry to enhance global risk governance capabilities [2] Group 2: Shanghai International Trade Center Development - Implementation of a "white list" management innovation for the inspection of imported consumer goods to streamline customs clearance for new products [4] - Development of an international data center in the Lingang New Area to promote data openness and international cooperation in digital trade [4] - Creation of a low-carbon energy refueling center for ships, positioning Shanghai as one of the few ports capable of LNG and green methanol refueling [4] Group 3: Shanghai International Technology Innovation Center Development - Establishment of a "basic research pilot zone" to enhance Shanghai's technological innovation capabilities [5] - Development of a synthetic biology innovation center to create a globally influential technology and industry hub [5] - Introduction of innovation vouchers that shift the approach from "finding policies from enterprises" to "policies finding enterprises," stimulating innovation and entrepreneurship [5]

Core Insights - On November 21, Zhifei Biological experienced a decline of 3.58% with a trading volume of 571 million yuan [1] - The company reported a net financing outflow of 16.49 million yuan on the same day, with a total financing and securities balance of 1.387 billion yuan [1][2] - For the period from January to September 2025, Zhifei Biological's revenue decreased by 66.53% year-on-year, amounting to 7.627 billion yuan, while the net profit attributable to shareholders was -1.206 billion yuan, a decrease of 156.10% [2] Financing and Securities - On November 21, Zhifei Biological had a financing buy-in of 63.06 million yuan, with a current financing balance of 1.384 billion yuan, representing 2.86% of the circulating market value [1] - The financing balance is below the 30th percentile level over the past year, indicating a low position [1] - The company had a securities lending balance of 3.5773 million yuan, which is above the 70th percentile level over the past year, indicating a high position [1] Shareholder Information - As of November 10, the number of shareholders for Zhifei Biological increased to 133,100, a rise of 1.19% [2] - The average number of circulating shares per shareholder decreased by 1.17% to 10,624 shares [2] - Major institutional shareholders have reduced their holdings, with Hong Kong Central Clearing Limited holding 33.5608 million shares, down by 2.7888 million shares [2]